Drug Topics
APRIL 29, 2025
Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.
STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 29, 2025
In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.
STAT
APRIL 29, 2025
The word came down at 9 a.m. Pacific on April 14 that they were done. Marcia Stefanick of Stanford and three other leaders of regional centers that for decades have researched women’s health heard from their study’s national leaders that their funding would end with the fiscal year. They all had contracts ready and waiting to be signed to extend their parts of the Women’s Health Initiative, a massive, groundbreaking study that has changed medical practice on hormone therapy,
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 29, 2025
The role of the community pharmacist is beginning to expand into specialty pharmacy spaces to increase access and outcomes for patients.
STAT
APRIL 29, 2025
After 15 years, the Affordable Care Act (ACA) has survived its share of challenges at the Supreme Court. On April 21, I attended the court’s first hearing in the latest of the series of ACA challenges, Kennedy v. Braidwood, which is focused on the ACA’s preventive services coverage requirement. I proudly represented 20 HIV advocacy organizations as amici in the case , urging the court to uphold the law, which requires payer coverage of items and
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 29, 2025
Gilead Sciences agreed to pay $202 million to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines, the latest example of a controversial practice that has come back to haunt numerous drugmakers over the years. From 2011 through 2017, Gilead held more than 17,300 speaker programs of which 9,500 were dinners to promote sales of HIV drugs that were supposed to be educational.
Drug Topics
APRIL 29, 2025
From medication dispensers to comprehensive patient care advocates, pharmacists have never been more essential to the health care team and to patients in specialty care.
PharmaVoice
APRIL 29, 2025
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
Drug Topics
APRIL 29, 2025
Luke Turnock, PhD, discusses the role of pharmacists and medication counselors in addressing the challenges of increased direct-to-consumer drug advertising on social media.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 29, 2025
Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies including Hims & Hers, Ro, and LifeMD. Novo last month launched a new direct-to-consumer website called NovoCare Pharmacy that sells Wegovy, which normally carries a list price of about $1,350 a month, at $499 a month to patients who are paying on their own without insurance.
The Checkup by Singlecare
APRIL 29, 2025
Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist, or GLP-1. It was originally approved by the U.S. Food and Drug Administration (FDA) in 2017 to help people with Type 2 diabetes manage their blood sugar levels. The injectable drug’s popularity soared when it was discovered that weight loss was an added bonus. Eventually, the FDA also approved another form of semaglutide , Wegovy , specifically for weight management.
STAT
APRIL 29, 2025
BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product. Analysts had estimated that the treatment, called Attruby, would bring in sales of $12 million, but Wall Street’s “whisper number” was $17 million to $20 million.
PhRMA
APRIL 29, 2025
America’s biopharmaceutical companies are committed to revitalizing American manufacturing, and they continue expanding their U.S. footprint. Supporting nearly five million jobs and more than 1,500 facilities across the U.S., we’re making investments that help develop new treatments and cures and contribute to America’s economy.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
APRIL 29, 2025
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we’ve got a bunch of news this morning about GLP-1 drugs, compounding, and biotechs’ interactions with the FDA. Let’s get into it.
Pharma Marketing Network
APRIL 29, 2025
Introduction Is traditional advertising losing its edge in the pharmaceutical world? As the industry shifts toward data-driven strategies, the power of audience targeting continues to redefine how brands connect with healthcare professionals (HCPs) and patients. While print ads, radio spots, and mass media campaigns once dominated, the ability to reach the right person at the right time through digital channels has quickly taken the lead.
STAT
APRIL 29, 2025
File this under “So close, yet so far.” After several years of struggling with regulatory hurdles to win approval for its rare disease drug, Stealth BioTherapeutics had expected the U.S. Food and Drug Administration to respond on Tuesday to its marketing application. But late last week, the company received a letter saying there was a delay.
Pharma Marketing Network
APRIL 29, 2025
Introduction When was the last time a glossy pharma ad truly resonated with a patient living with chronic illness? In today’s healthcare marketing landscape, trust is the new currencyand real stories matter more than polished commercials. Thats why Influencer Marketing In Pharma is gaining momentum as a critical tool for reaching audiences in a more authentic, impactful way.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
APRIL 29, 2025
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. As of last week, Chris Klomp is in charge of the Center for Medicare. Unlike predecessors, he’s not a policy wonk.
PhRMA
APRIL 29, 2025
Today, the Office of the U.S. Trade Representative (USTR) released the 2025 Special 301 Report. PhRMA welcomes USTR’s commitment to defending American innovation against harmful IP and market access practices in trading partners across the globe.
STAT
APRIL 29, 2025
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to terrorize. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is roasted coconut — and attack the fast-growing to-do list.
Pharmafile
APRIL 29, 2025
The EU has granted marketing authorisation (MA) for Filspari CSL Vifor and Travere Therapeutics therapy for primary IgA nephropathy (IgAN), a rare kidney disease advancing the ability to administer the therapy to patients globally. Filspari is a dual endothelin angiotensin receptor antagonist(DEARA), a non-immunosuppressive therapy for the treatment of IgAN.
European Pharmaceutical Review
APRIL 29, 2025
The US Pharmacopeia (USP) has launched a selection of resources, including reference materials and standards, to support developers and manufacturers of AAV-based gene therapies. Alongside these resources, USP is publishing the proposed General Chapter <1067> AAV Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Products.
Pharmafile
APRIL 29, 2025
Gifthealth, a technology-driven pharmacy care company, has appointed Chip Parkinson as its new chief executive officer. The move marks a strategic step in accelerating the companys mission to improve prescription efficiency and accessibility through its digital platform. Parkinson brings over three decades of leadership experience across biotech, pharmacy benefit management, diagnostics and pharma industries.
The Checkup by Singlecare
APRIL 29, 2025
There is a common misconception that antibiotics can treat vaginal yeast infections, despite being primarily intended for certain types of bacterial infections. However, this medication can trigger the overgrowth of yeast, which is why antifungals are the recommended medications for treating yeast infections. Can antibiotics treat yeast infections? No, antibiotics cannot treat vaginal yeast infections.
DiversifyRx
APRIL 29, 2025
Should You Keep Compounding GLP1s (Tirzepatide or Semaglutide) After the FDA Deadline? Here’s My Take. Howdy pharmacy peeps… Lets have a real talk about compounding GLP1s. Theres been a lot of chatter lately in the pharmacy worldforums, Facebook groups, emails, even conference hallwaysabout whether pharmacies should keep compounding GLP1s tirzepatide/semaglutide once the FDA deadlines pass.
Board Vitals - Pharmacist
APRIL 29, 2025
Getting ready for your board exam is a big step in your professional career. While the pressure to do well can be intense, having the right strategy and study resources is key. Following a six-month study plan will help you cover all the essential material while you build your confidence for exam day. Why Should You Study for 6 Months? Between work and other responsibilities, you likely have enough to do without worrying about preparing for your board exams.
The Checkup by Singlecare
APRIL 29, 2025
Cequa is a prescription eye drop used in the treatment of dry eye disease. The ophthalmic solution has an immune-suppressing active ingredient, cyclosporine. For those suffering from dry eye symptoms, such as redness, irritation, burning, blurred vision, and light sensitivity, Cequa can provide welcome relief if other treatment measures are ineffective.
Pharmafile
APRIL 29, 2025
Global R&D sample stability and biorepository storage company, Astoriom, has announced the appointment of Ryan Smith as global head of sales, supporting the companys ambition to continue advancing internationally. Having led global commercial teams in life sciences for over two decades, Smith has thorough experience in delivering revenue growth, improving commercial processes and scaling global […] The post Ryan Smith appointed as global head of sales at Astoriom appeared first on Phar
Pharmaceutical Technology
APRIL 29, 2025
The EC has granted conditional marketing approval to Regeneron Pharmaceuticals bispecific antibody Lynozyfic for treating multiple myeloma.
Fierce Healthcare
APRIL 29, 2025
The ruling implies that HHS did not underfund hospitals from 2006 to 2009, as the plaintiffs argue.
Pharmaceutical Technology
APRIL 29, 2025
Prilenia has signed a partnership and licence agreement with Ferrer for jointly developing and commercialising pridopidine in Europe.
Fierce Healthcare
APRIL 29, 2025
Novo Nordisk and Hims & Hers have struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs. The Danish drugmaker is making its blockbuster drug Wegovy available through the Hims' platform as well as other telehealth companies LifeMD and Ro.
Expert insights. Personalized for you.
546 
Let's personalize your content